D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC ...

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $34.0, a high estimate of $46.00 ...

此次调整是在公司上周五宣布其管线更新后做出的。4D Molecular Therapeutics强调了其4D-150项目在湿性年龄相关性黄斑变性（wAMD）和糖尿病黄斑水肿（DME）治疗方面的优先地位，以及4D-710在囊性纤维化（CF）治疗方面的重要性。

Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), retaining the price ...

周一，BMO Capital Markets将4D Molecular Therapeutics (NASDAQ:FDMT)的评级从"跑赢大市"下调至"市场表现"，目标价定为$15.00。该股目前交易价格为$5.52，过去一年下跌近71%，接近其52周低点$5.22。

BofA lowered the firm’s price target on 4D Molecular (FDMT) to $42 from $46 on Friday and kept a Buy rating on the shares. The firm notes 4D ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...

D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical ...

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter ...